Today: 11 June 2026
Browse Category

NYSE:CQP 14 January 2026

Stock Market Today

  • Crude Oil Prices Drop Sharply Amid US-Iran Peace Hopes and Volatility
    June 11, 2026, 5:42 PM EDT. Crude oil prices fell sharply on Thursday, with July WTI crude closing down 2.58%, as President Trump canceled planned military strikes on Iran, signaling imminent peace talks. Early in the session, prices surged on threats to seize Kharg Island, Iran's main export hub, reflecting heightened Middle East tensions. Volatility was fueled by mixed signals: continued US naval blockade of the Strait of Hormuz versus rising oil flows and weak Chinese demand. China's crude imports dropped to an eight-year low, adding bearish pressure. The U.S. Department of Energy raised its 2026 crude production forecast, weighing on prices further. Ukrainian drone attacks on Russian oil infrastructure provided some support amid the complex geopolitical and supply-demand dynamics affecting global oil markets.

Latest articles

Bradesco Shares Rise, BBDC4 and BBD ADRs Track Brazil Market Recovery

Bradesco Shares Rise, BBDC4 and BBD ADRs Track Brazil Market Recovery

11 June 2026
Bradesco’s preferred shares jumped to R$17.67 and U.S. ADRs to $3.44 with heavy volume as Brazil’s Ibovespa surged 1.71%, spotlighting the lender after reporting a 16.1% year-over-year rise in recurring net income to R$6.811 billion in 1Q26; board and executive insiders sold non-voting shares, while the controlling group’s stake remained unchanged.
Bank of Nova Scotia Hits 52-Week High; TSX Bounces Back

Bank of Nova Scotia Hits 52-Week High; TSX Bounces Back

11 June 2026
Bank of Nova Scotia surged to a 52-week high, closing up 1.24% at C$115.27 in Toronto after announcing expanded AI adoption across its workforce and higher Q2 earnings, while the S&P/TSX Composite jumped 1.5% as financials rallied and trading volume soared above average.
Moderna Gains Almost 8% With Nasdaq Recovery; Cancer Vaccine Pipeline Still a Key Focus

Moderna Gains Almost 8% With Nasdaq Recovery; Cancer Vaccine Pipeline Still a Key Focus

11 June 2026
Moderna surged 7.94% to $49.64 as U.S. stocks rebounded sharply, with investors eyeing its mRNA cancer-vaccine pipeline after a UK trial authorization; Wall Street’s average analyst rating remains “Hold” with a $43.30 target, and BofA raised its price target to $34 citing norovirus prospects, while Moderna reported Q1 revenue of $389 million and a $1.3 billion net loss.
Go toTop